nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—ovarian cancer	0.205	0.542	CbGaD
Vandetanib—EGFR—ovarian cancer	0.173	0.458	CbGaD
Vandetanib—EGFR—Docetaxel—ovarian cancer	0.0712	0.278	CbGbCtD
Vandetanib—ABCG2—Topotecan—ovarian cancer	0.0328	0.128	CbGbCtD
Vandetanib—ABCC1—Epirubicin—ovarian cancer	0.0246	0.0963	CbGbCtD
Vandetanib—ABCC1—Paclitaxel—ovarian cancer	0.0243	0.095	CbGbCtD
Vandetanib—ABCC1—Docetaxel—ovarian cancer	0.0176	0.0687	CbGbCtD
Vandetanib—ABCG2—Paclitaxel—ovarian cancer	0.0163	0.0636	CbGbCtD
Vandetanib—ABCG2—Carboplatin—ovarian cancer	0.0153	0.0598	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—ovarian cancer	0.0131	0.0512	CbGbCtD
Vandetanib—ABCG2—Docetaxel—ovarian cancer	0.0118	0.046	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—ovarian cancer	0.00876	0.0343	CbGbCtD
Vandetanib—CYP3A4—Topotecan—ovarian cancer	0.0071	0.0277	CbGbCtD
Vandetanib—CYP3A4—Vinorelbine—ovarian cancer	0.005	0.0195	CbGbCtD
Vandetanib—CYP3A4—Paclitaxel—ovarian cancer	0.00351	0.0137	CbGbCtD
Vandetanib—CYP3A4—Docetaxel—ovarian cancer	0.00254	0.00993	CbGbCtD
Vandetanib—CYP3A4—Doxorubicin—ovarian cancer	0.00189	0.0074	CbGbCtD
Vandetanib—Afatinib—ERBB2—ovarian cancer	0.00131	0.251	CrCbGaD
Vandetanib—Gefitinib—CHEK2—ovarian cancer	0.000685	0.131	CrCbGaD
Vandetanib—Bosutinib—CHEK2—ovarian cancer	0.000674	0.129	CrCbGaD
Vandetanib—Afatinib—EGFR—ovarian cancer	0.000619	0.119	CrCbGaD
Vandetanib—ERBB3—Vinblastine—Vinorelbine—ovarian cancer	0.000533	0.198	CbGdCrCtD
Vandetanib—Erlotinib—CYP1B1—ovarian cancer	0.000463	0.0888	CrCbGaD
Vandetanib—Erlotinib—EGFR—ovarian cancer	0.000437	0.0838	CrCbGaD
Vandetanib—TYRO3—female gonad—ovarian cancer	0.000422	0.00411	CbGeAlD
Vandetanib—AXL—uterine cervix—ovarian cancer	0.00042	0.0041	CbGeAlD
Vandetanib—IRAK4—endometrium—ovarian cancer	0.000419	0.00409	CbGeAlD
Vandetanib—EPHA5—vagina—ovarian cancer	0.000419	0.00409	CbGeAlD
Vandetanib—BMPR1B—female gonad—ovarian cancer	0.000413	0.00403	CbGeAlD
Vandetanib—EGFR—uterus—ovarian cancer	0.000408	0.00398	CbGeAlD
Vandetanib—MKNK1—decidua—ovarian cancer	0.000407	0.00397	CbGeAlD
Vandetanib—SLK—uterine cervix—ovarian cancer	0.000404	0.00394	CbGeAlD
Vandetanib—MAP2K5—myometrium—ovarian cancer	0.000403	0.00393	CbGeAlD
Vandetanib—KDR—myometrium—ovarian cancer	0.000403	0.00393	CbGeAlD
Vandetanib—EPHA6—testis—ovarian cancer	0.000403	0.00393	CbGeAlD
Vandetanib—LCK—decidua—ovarian cancer	0.000402	0.00392	CbGeAlD
Vandetanib—RET—decidua—ovarian cancer	0.000402	0.00392	CbGeAlD
Vandetanib—FGR—decidua—ovarian cancer	0.000402	0.00392	CbGeAlD
Vandetanib—AXL—decidua—ovarian cancer	0.0004	0.0039	CbGeAlD
Vandetanib—PLK4—testis—ovarian cancer	0.000398	0.00388	CbGeAlD
Vandetanib—VEGFA—uterus—ovarian cancer	0.000395	0.00385	CbGeAlD
Vandetanib—FLT3—female reproductive system—ovarian cancer	0.000394	0.00384	CbGeAlD
Vandetanib—FYN—uterine cervix—ovarian cancer	0.000393	0.00383	CbGeAlD
Vandetanib—KDR—embryo—ovarian cancer	0.000388	0.00378	CbGeAlD
Vandetanib—TEK—epithelium—ovarian cancer	0.000387	0.00378	CbGeAlD
Vandetanib—MKNK1—endometrium—ovarian cancer	0.000386	0.00377	CbGeAlD
Vandetanib—STK35—female reproductive system—ovarian cancer	0.000386	0.00376	CbGeAlD
Vandetanib—SLK—decidua—ovarian cancer	0.000385	0.00376	CbGeAlD
Vandetanib—MAP4K5—uterine cervix—ovarian cancer	0.000384	0.00375	CbGeAlD
Vandetanib—FGR—endometrium—ovarian cancer	0.000381	0.00372	CbGeAlD
Vandetanib—AXL—endometrium—ovarian cancer	0.00038	0.0037	CbGeAlD
Vandetanib—ERBB3—uterus—ovarian cancer	0.000379	0.0037	CbGeAlD
Vandetanib—FYN—decidua—ovarian cancer	0.000374	0.00365	CbGeAlD
Vandetanib—TYRO3—testis—ovarian cancer	0.000374	0.00365	CbGeAlD
Vandetanib—FLT3—bone marrow—ovarian cancer	0.000372	0.00363	CbGeAlD
Vandetanib—BLK—lymph node—ovarian cancer	0.00037	0.0036	CbGeAlD
Vandetanib—EPHB6—uterine cervix—ovarian cancer	0.000367	0.00358	CbGeAlD
Vandetanib—BMPR1B—testis—ovarian cancer	0.000366	0.00357	CbGeAlD
Vandetanib—MAP3K19—testis—ovarian cancer	0.000366	0.00357	CbGeAlD
Vandetanib—TEK—decidua—ovarian cancer	0.000366	0.00357	CbGeAlD
Vandetanib—MAP4K5—decidua—ovarian cancer	0.000366	0.00357	CbGeAlD
Vandetanib—SLK—endometrium—ovarian cancer	0.000366	0.00357	CbGeAlD
Vandetanib—LTK—lymph node—ovarian cancer	0.000365	0.00356	CbGeAlD
Vandetanib—FLT3—female gonad—ovarian cancer	0.000358	0.0035	CbGeAlD
Vandetanib—MKNK1—gonad—ovarian cancer	0.000358	0.00349	CbGeAlD
Vandetanib—FLT4—female reproductive system—ovarian cancer	0.000358	0.00349	CbGeAlD
Vandetanib—RIPK2—female reproductive system—ovarian cancer	0.000356	0.00347	CbGeAlD
Vandetanib—FYN—endometrium—ovarian cancer	0.000355	0.00347	CbGeAlD
Vandetanib—YES1—uterine cervix—ovarian cancer	0.000355	0.00346	CbGeAlD
Vandetanib—AXL—gonad—ovarian cancer	0.000352	0.00344	CbGeAlD
Vandetanib—STK10—uterine cervix—ovarian cancer	0.000351	0.00343	CbGeAlD
Vandetanib—LCK—uterus—ovarian cancer	0.000351	0.00343	CbGeAlD
Vandetanib—STK35—female gonad—ovarian cancer	0.000351	0.00343	CbGeAlD
Vandetanib—AXL—uterus—ovarian cancer	0.00035	0.00341	CbGeAlD
Vandetanib—EPHB6—decidua—ovarian cancer	0.00035	0.00341	CbGeAlD
Vandetanib—PDGFRB—myometrium—ovarian cancer	0.000349	0.00341	CbGeAlD
Vandetanib—STK35—vagina—ovarian cancer	0.000349	0.0034	CbGeAlD
Vandetanib—TEK—endometrium—ovarian cancer	0.000347	0.00339	CbGeAlD
Vandetanib—MAP4K5—endometrium—ovarian cancer	0.000347	0.00339	CbGeAlD
Vandetanib—SRC—epithelium—ovarian cancer	0.000344	0.00336	CbGeAlD
Vandetanib—ABL2—female gonad—ovarian cancer	0.000342	0.00334	CbGeAlD
Vandetanib—SRC—uterine cervix—ovarian cancer	0.000341	0.00333	CbGeAlD
Vandetanib—ERBB3—female reproductive system—ovarian cancer	0.000341	0.00332	CbGeAlD
Vandetanib—ABL2—vagina—ovarian cancer	0.00034	0.00332	CbGeAlD
Vandetanib—YES1—decidua—ovarian cancer	0.000338	0.0033	CbGeAlD
Vandetanib—FLT4—bone marrow—ovarian cancer	0.000338	0.00329	CbGeAlD
Vandetanib—SLK—uterus—ovarian cancer	0.000337	0.00329	CbGeAlD
Vandetanib—RIPK2—bone marrow—ovarian cancer	0.000336	0.00328	CbGeAlD
Vandetanib—PDGFRB—embryo—ovarian cancer	0.000336	0.00328	CbGeAlD
Vandetanib—VEGFA—bone marrow—ovarian cancer	0.000335	0.00327	CbGeAlD
Vandetanib—STK10—decidua—ovarian cancer	0.000335	0.00327	CbGeAlD
Vandetanib—EGFR—female gonad—ovarian cancer	0.000334	0.00326	CbGeAlD
Vandetanib—EPHB6—endometrium—ovarian cancer	0.000332	0.00324	CbGeAlD
Vandetanib—IRAK4—bone marrow—ovarian cancer	0.000328	0.0032	CbGeAlD
Vandetanib—FYN—uterus—ovarian cancer	0.000328	0.0032	CbGeAlD
Vandetanib—FLT4—female gonad—ovarian cancer	0.000326	0.00318	CbGeAlD
Vandetanib—SRC—decidua—ovarian cancer	0.000325	0.00317	CbGeAlD
Vandetanib—RIPK2—female gonad—ovarian cancer	0.000324	0.00316	CbGeAlD
Vandetanib—VEGFA—female gonad—ovarian cancer	0.000323	0.00315	CbGeAlD
Vandetanib—MAP4K5—gonad—ovarian cancer	0.000322	0.00314	CbGeAlD
Vandetanib—RIPK2—vagina—ovarian cancer	0.000322	0.00314	CbGeAlD
Vandetanib—FMO1—female gonad—ovarian cancer	0.000321	0.00313	CbGeAlD
Vandetanib—VEGFA—vagina—ovarian cancer	0.000321	0.00313	CbGeAlD
Vandetanib—YES1—endometrium—ovarian cancer	0.000321	0.00313	CbGeAlD
Vandetanib—MAP4K5—uterus—ovarian cancer	0.00032	0.00312	CbGeAlD
Vandetanib—TEK—uterus—ovarian cancer	0.00032	0.00312	CbGeAlD
Vandetanib—MKNK1—female reproductive system—ovarian cancer	0.00032	0.00312	CbGeAlD
Vandetanib—FMO1—vagina—ovarian cancer	0.000319	0.00311	CbGeAlD
Vandetanib—FLT3—testis—ovarian cancer	0.000318	0.0031	CbGeAlD
Vandetanib—KDR—epithelium—ovarian cancer	0.000317	0.00309	CbGeAlD
Vandetanib—IRAK4—female gonad—ovarian cancer	0.000316	0.00308	CbGeAlD
Vandetanib—FGR—female reproductive system—ovarian cancer	0.000316	0.00308	CbGeAlD
Vandetanib—AXL—female reproductive system—ovarian cancer	0.000315	0.00307	CbGeAlD
Vandetanib—IRAK4—vagina—ovarian cancer	0.000314	0.00307	CbGeAlD
Vandetanib—KDR—uterine cervix—ovarian cancer	0.000314	0.00306	CbGeAlD
Vandetanib—MAP2K5—uterine cervix—ovarian cancer	0.000314	0.00306	CbGeAlD
Vandetanib—STK35—testis—ovarian cancer	0.000311	0.00304	CbGeAlD
Vandetanib—ABL1—myometrium—ovarian cancer	0.000311	0.00304	CbGeAlD
Vandetanib—ERBB3—female gonad—ovarian cancer	0.00031	0.00302	CbGeAlD
Vandetanib—ABL2—testis—ovarian cancer	0.000303	0.00296	CbGeAlD
Vandetanib—MKNK1—bone marrow—ovarian cancer	0.000302	0.00294	CbGeAlD
Vandetanib—ABL1—embryo—ovarian cancer	0.000299	0.00292	CbGeAlD
Vandetanib—MAP2K5—decidua—ovarian cancer	0.000299	0.00292	CbGeAlD
Vandetanib—KDR—decidua—ovarian cancer	0.000299	0.00292	CbGeAlD
Vandetanib—FGR—bone marrow—ovarian cancer	0.000298	0.00291	CbGeAlD
Vandetanib—LCK—bone marrow—ovarian cancer	0.000298	0.00291	CbGeAlD
Vandetanib—YES1—gonad—ovarian cancer	0.000298	0.0029	CbGeAlD
Vandetanib—EGFR—testis—ovarian cancer	0.000296	0.00289	CbGeAlD
Vandetanib—YES1—uterus—ovarian cancer	0.000296	0.00288	CbGeAlD
Vandetanib—STK10—gonad—ovarian cancer	0.000295	0.00288	CbGeAlD
Vandetanib—FYN—female reproductive system—ovarian cancer	0.000294	0.00287	CbGeAlD
Vandetanib—STK10—uterus—ovarian cancer	0.000293	0.00286	CbGeAlD
Vandetanib—MKNK1—female gonad—ovarian cancer	0.000291	0.00284	CbGeAlD
Vandetanib—MKNK1—vagina—ovarian cancer	0.000289	0.00282	CbGeAlD
Vandetanib—FLT4—testis—ovarian cancer	0.000289	0.00282	CbGeAlD
Vandetanib—PLK4—lymph node—ovarian cancer	0.000288	0.00281	CbGeAlD
Vandetanib—TEK—female reproductive system—ovarian cancer	0.000288	0.00281	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—ovarian cancer	0.000288	0.00281	CbGeAlD
Vandetanib—FGR—female gonad—ovarian cancer	0.000287	0.0028	CbGeAlD
Vandetanib—LCK—female gonad—ovarian cancer	0.000287	0.0028	CbGeAlD
Vandetanib—RIPK2—testis—ovarian cancer	0.000287	0.0028	CbGeAlD
Vandetanib—VEGFA—testis—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—AXL—female gonad—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—SRC—gonad—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—SLK—bone marrow—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—LCK—vagina—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—FGR—vagina—ovarian cancer	0.000286	0.00279	CbGeAlD
Vandetanib—AXL—vagina—ovarian cancer	0.000285	0.00278	CbGeAlD
Vandetanib—KDR—endometrium—ovarian cancer	0.000284	0.00277	CbGeAlD
Vandetanib—MAP2K5—endometrium—ovarian cancer	0.000284	0.00277	CbGeAlD
Vandetanib—IRAK4—testis—ovarian cancer	0.00028	0.00274	CbGeAlD
Vandetanib—FYN—bone marrow—ovarian cancer	0.000278	0.00271	CbGeAlD
Vandetanib—FMO3—vagina—ovarian cancer	0.000276	0.00269	CbGeAlD
Vandetanib—SLK—female gonad—ovarian cancer	0.000276	0.00269	CbGeAlD
Vandetanib—ERBB3—testis—ovarian cancer	0.000275	0.00268	CbGeAlD
Vandetanib—PDGFRB—epithelium—ovarian cancer	0.000274	0.00267	CbGeAlD
Vandetanib—SLK—vagina—ovarian cancer	0.000274	0.00267	CbGeAlD
Vandetanib—Gefitinib—EGFR—ovarian cancer	0.000274	0.0525	CrCbGaD
Vandetanib—PDGFRB—uterine cervix—ovarian cancer	0.000272	0.00265	CbGeAlD
Vandetanib—MAP4K5—bone marrow—ovarian cancer	0.000272	0.00265	CbGeAlD
Vandetanib—Bosutinib—EGFR—ovarian cancer	0.000269	0.0516	CrCbGaD
Vandetanib—FYN—female gonad—ovarian cancer	0.000268	0.00261	CbGeAlD
Vandetanib—FYN—vagina—ovarian cancer	0.000266	0.0026	CbGeAlD
Vandetanib—YES1—female reproductive system—ovarian cancer	0.000266	0.00259	CbGeAlD
Vandetanib—BMPR1B—lymph node—ovarian cancer	0.000265	0.00259	CbGeAlD
Vandetanib—STK10—female reproductive system—ovarian cancer	0.000263	0.00257	CbGeAlD
Vandetanib—MAP4K5—female gonad—ovarian cancer	0.000262	0.00255	CbGeAlD
Vandetanib—TEK—female gonad—ovarian cancer	0.000262	0.00255	CbGeAlD
Vandetanib—KDR—uterus—ovarian cancer	0.000262	0.00255	CbGeAlD
Vandetanib—MAP4K5—vagina—ovarian cancer	0.00026	0.00254	CbGeAlD
Vandetanib—PDGFRB—decidua—ovarian cancer	0.000259	0.00252	CbGeAlD
Vandetanib—MKNK1—testis—ovarian cancer	0.000258	0.00252	CbGeAlD
Vandetanib—SRC—female reproductive system—ovarian cancer	0.000256	0.00249	CbGeAlD
Vandetanib—RET—testis—ovarian cancer	0.000255	0.00249	CbGeAlD
Vandetanib—LCK—testis—ovarian cancer	0.000255	0.00249	CbGeAlD
Vandetanib—FGR—testis—ovarian cancer	0.000255	0.00249	CbGeAlD
Vandetanib—AXL—testis—ovarian cancer	0.000254	0.00248	CbGeAlD
Vandetanib—YES1—bone marrow—ovarian cancer	0.000251	0.00245	CbGeAlD
Vandetanib—EPHB6—female gonad—ovarian cancer	0.00025	0.00244	CbGeAlD
Vandetanib—EPHB6—vagina—ovarian cancer	0.000249	0.00243	CbGeAlD
Vandetanib—STK10—bone marrow—ovarian cancer	0.000249	0.00243	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Epirubicin—ovarian cancer	0.000247	0.0921	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—ovarian cancer	0.000247	0.0921	CbGdCrCtD
Vandetanib—FMO3—testis—ovarian cancer	0.000246	0.0024	CbGeAlD
Vandetanib—PDGFRB—endometrium—ovarian cancer	0.000246	0.0024	CbGeAlD
Vandetanib—SLK—testis—ovarian cancer	0.000244	0.00238	CbGeAlD
Vandetanib—ABL1—uterine cervix—ovarian cancer	0.000242	0.00236	CbGeAlD
Vandetanib—YES1—female gonad—ovarian cancer	0.000242	0.00236	CbGeAlD
Vandetanib—YES1—vagina—ovarian cancer	0.00024	0.00234	CbGeAlD
Vandetanib—STK10—female gonad—ovarian cancer	0.00024	0.00234	CbGeAlD
Vandetanib—STK10—vagina—ovarian cancer	0.000238	0.00232	CbGeAlD
Vandetanib—FYN—testis—ovarian cancer	0.000238	0.00232	CbGeAlD
Vandetanib—ABCC1—myometrium—ovarian cancer	0.000237	0.00231	CbGeAlD
Vandetanib—KDR—female reproductive system—ovarian cancer	0.000235	0.00229	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—ovarian cancer	0.000235	0.00229	CbGeAlD
Vandetanib—SRC—female gonad—ovarian cancer	0.000233	0.00227	CbGeAlD
Vandetanib—TEK—testis—ovarian cancer	0.000232	0.00227	CbGeAlD
Vandetanib—MAP4K5—testis—ovarian cancer	0.000232	0.00227	CbGeAlD
Vandetanib—ABL1—decidua—ovarian cancer	0.000231	0.00225	CbGeAlD
Vandetanib—ORM1—endometrium—ovarian cancer	0.00023	0.00225	CbGeAlD
Vandetanib—FLT3—lymph node—ovarian cancer	0.00023	0.00225	CbGeAlD
Vandetanib—PLK4—Idarubicin—Doxorubicin—ovarian cancer	0.000229	0.0852	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—ovarian cancer	0.000229	0.0852	CbGdCrCtD
Vandetanib—PDGFRB—gonad—ovarian cancer	0.000228	0.00222	CbGeAlD
Vandetanib—PDGFRB—uterus—ovarian cancer	0.000226	0.00221	CbGeAlD
Vandetanib—STK35—lymph node—ovarian cancer	0.000226	0.0022	CbGeAlD
Vandetanib—KDR—bone marrow—ovarian cancer	0.000222	0.00217	CbGeAlD
Vandetanib—EPHB6—testis—ovarian cancer	0.000222	0.00216	CbGeAlD
Vandetanib—ABL2—lymph node—ovarian cancer	0.00022	0.00215	CbGeAlD
Vandetanib—ABL1—endometrium—ovarian cancer	0.000219	0.00214	CbGeAlD
Vandetanib—EGFR—lymph node—ovarian cancer	0.000215	0.00209	CbGeAlD
Vandetanib—YES1—testis—ovarian cancer	0.000214	0.00209	CbGeAlD
Vandetanib—MAP2K5—female gonad—ovarian cancer	0.000214	0.00209	CbGeAlD
Vandetanib—KDR—female gonad—ovarian cancer	0.000214	0.00209	CbGeAlD
Vandetanib—KDR—vagina—ovarian cancer	0.000213	0.00207	CbGeAlD
Vandetanib—MAP2K5—vagina—ovarian cancer	0.000213	0.00207	CbGeAlD
Vandetanib—STK10—testis—ovarian cancer	0.000213	0.00207	CbGeAlD
Vandetanib—FLT4—lymph node—ovarian cancer	0.000209	0.00204	CbGeAlD
Vandetanib—RIPK2—lymph node—ovarian cancer	0.000208	0.00203	CbGeAlD
Vandetanib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000208	0.0774	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000208	0.0774	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000208	0.0774	CbGdCrCtD
Vandetanib—VEGFA—lymph node—ovarian cancer	0.000208	0.00203	CbGeAlD
Vandetanib—FMO1—lymph node—ovarian cancer	0.000206	0.00201	CbGeAlD
Vandetanib—SRC—testis—ovarian cancer	0.000206	0.00201	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—ovarian cancer	0.000204	0.00199	CbGeAlD
Vandetanib—IRAK4—lymph node—ovarian cancer	0.000203	0.00198	CbGeAlD
Vandetanib—ABL1—gonad—ovarian cancer	0.000203	0.00198	CbGeAlD
Vandetanib—ABL1—uterus—ovarian cancer	0.000202	0.00197	CbGeAlD
Vandetanib—ERBB3—lymph node—ovarian cancer	0.000199	0.00194	CbGeAlD
Vandetanib—ABCG2—myometrium—ovarian cancer	0.000196	0.00191	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000192	0.0716	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000192	0.0716	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000192	0.0716	CbGdCrCtD
Vandetanib—PDGFRB—bone marrow—ovarian cancer	0.000192	0.00187	CbGeAlD
Vandetanib—ORM1—female reproductive system—ovarian cancer	0.000191	0.00186	CbGeAlD
Vandetanib—KDR—testis—ovarian cancer	0.00019	0.00185	CbGeAlD
Vandetanib—MAP2K5—testis—ovarian cancer	0.00019	0.00185	CbGeAlD
Vandetanib—Afatinib—ABCB1—ovarian cancer	0.000188	0.0361	CrCbGaD
Vandetanib—MKNK1—lymph node—ovarian cancer	0.000187	0.00182	CbGeAlD
Vandetanib—PDGFRB—female gonad—ovarian cancer	0.000185	0.00181	CbGeAlD
Vandetanib—FGR—lymph node—ovarian cancer	0.000185	0.0018	CbGeAlD
Vandetanib—LCK—lymph node—ovarian cancer	0.000185	0.0018	CbGeAlD
Vandetanib—RET—lymph node—ovarian cancer	0.000185	0.0018	CbGeAlD
Vandetanib—ABCC1—uterine cervix—ovarian cancer	0.000184	0.0018	CbGeAlD
Vandetanib—PDGFRB—vagina—ovarian cancer	0.000184	0.0018	CbGeAlD
Vandetanib—AXL—lymph node—ovarian cancer	0.000184	0.0018	CbGeAlD
Vandetanib—ABL1—female reproductive system—ovarian cancer	0.000181	0.00177	CbGeAlD
Vandetanib—ORM1—bone marrow—ovarian cancer	0.00018	0.00176	CbGeAlD
Vandetanib—FMO3—lymph node—ovarian cancer	0.000178	0.00174	CbGeAlD
Vandetanib—SLK—lymph node—ovarian cancer	0.000177	0.00173	CbGeAlD
Vandetanib—ABCC1—decidua—ovarian cancer	0.000176	0.00171	CbGeAlD
Vandetanib—FYN—lymph node—ovarian cancer	0.000172	0.00168	CbGeAlD
Vandetanib—ABL1—bone marrow—ovarian cancer	0.000171	0.00167	CbGeAlD
Vandetanib—MAP4K5—lymph node—ovarian cancer	0.000168	0.00164	CbGeAlD
Vandetanib—TEK—lymph node—ovarian cancer	0.000168	0.00164	CbGeAlD
Vandetanib—ABCC1—endometrium—ovarian cancer	0.000167	0.00163	CbGeAlD
Vandetanib—ABL1—female gonad—ovarian cancer	0.000165	0.00161	CbGeAlD
Vandetanib—PDGFRB—testis—ovarian cancer	0.000164	0.0016	CbGeAlD
Vandetanib—ABL1—vagina—ovarian cancer	0.000164	0.0016	CbGeAlD
Vandetanib—EPHB6—lymph node—ovarian cancer	0.000161	0.00157	CbGeAlD
Vandetanib—YES1—lymph node—ovarian cancer	0.000155	0.00152	CbGeAlD
Vandetanib—STK10—lymph node—ovarian cancer	0.000154	0.0015	CbGeAlD
Vandetanib—ABCC1—uterus—ovarian cancer	0.000154	0.0015	CbGeAlD
Vandetanib—ABCG2—uterine cervix—ovarian cancer	0.000153	0.00149	CbGeAlD
Vandetanib—SRC—lymph node—ovarian cancer	0.00015	0.00146	CbGeAlD
Vandetanib—ABL1—testis—ovarian cancer	0.000146	0.00143	CbGeAlD
Vandetanib—ABCG2—decidua—ovarian cancer	0.000145	0.00142	CbGeAlD
Vandetanib—ABCG2—endometrium—ovarian cancer	0.000138	0.00135	CbGeAlD
Vandetanib—MAP2K5—lymph node—ovarian cancer	0.000138	0.00134	CbGeAlD
Vandetanib—KDR—lymph node—ovarian cancer	0.000138	0.00134	CbGeAlD
Vandetanib—ALB—testis—ovarian cancer	0.000135	0.00132	CbGeAlD
Vandetanib—Erlotinib—ABCB1—ovarian cancer	0.000133	0.0255	CrCbGaD
Vandetanib—ABCG2—uterus—ovarian cancer	0.000127	0.00124	CbGeAlD
Vandetanib—ABCC1—female gonad—ovarian cancer	0.000126	0.00123	CbGeAlD
Vandetanib—ABCC1—vagina—ovarian cancer	0.000125	0.00122	CbGeAlD
Vandetanib—PDGFRB—lymph node—ovarian cancer	0.000119	0.00116	CbGeAlD
Vandetanib—ORM1—lymph node—ovarian cancer	0.000112	0.00109	CbGeAlD
Vandetanib—ABCC1—testis—ovarian cancer	0.000112	0.00109	CbGeAlD
Vandetanib—ABCG2—bone marrow—ovarian cancer	0.000108	0.00105	CbGeAlD
Vandetanib—ABL1—lymph node—ovarian cancer	0.000106	0.00104	CbGeAlD
Vandetanib—ABCG2—female gonad—ovarian cancer	0.000104	0.00102	CbGeAlD
Vandetanib—ABCG2—vagina—ovarian cancer	0.000103	0.00101	CbGeAlD
Vandetanib—ALB—lymph node—ovarian cancer	9.79e-05	0.000955	CbGeAlD
Vandetanib—Convulsion—Paclitaxel—ovarian cancer	9.3e-05	0.000942	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—ovarian cancer	9.27e-05	0.000939	CcSEcCtD
Vandetanib—Hypertension—Paclitaxel—ovarian cancer	9.26e-05	0.000938	CcSEcCtD
Vandetanib—Alopecia—Docetaxel—ovarian cancer	9.23e-05	0.000935	CcSEcCtD
Vandetanib—ABCG2—testis—ovarian cancer	9.23e-05	0.000901	CbGeAlD
Vandetanib—Pruritus—Vinorelbine—ovarian cancer	9.21e-05	0.000933	CcSEcCtD
Vandetanib—Mental disorder—Docetaxel—ovarian cancer	9.15e-05	0.000927	CcSEcCtD
Vandetanib—Chest pain—Paclitaxel—ovarian cancer	9.14e-05	0.000925	CcSEcCtD
Vandetanib—Arthralgia—Paclitaxel—ovarian cancer	9.14e-05	0.000925	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—ovarian cancer	9.11e-05	0.000923	CcSEcCtD
Vandetanib—Anxiety—Paclitaxel—ovarian cancer	9.1e-05	0.000922	CcSEcCtD
Vandetanib—Malnutrition—Docetaxel—ovarian cancer	9.09e-05	0.000921	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	9.07e-05	0.000919	CcSEcCtD
Vandetanib—Nausea—Topotecan—ovarian cancer	9.04e-05	0.000916	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—ovarian cancer	9.02e-05	0.000913	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	8.98e-05	0.00091	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—ovarian cancer	8.96e-05	0.000908	CcSEcCtD
Vandetanib—Dry mouth—Paclitaxel—ovarian cancer	8.93e-05	0.000905	CcSEcCtD
Vandetanib—Diarrhoea—Vinorelbine—ovarian cancer	8.91e-05	0.000902	CcSEcCtD
Vandetanib—Dysgeusia—Docetaxel—ovarian cancer	8.91e-05	0.000902	CcSEcCtD
Vandetanib—Nausea—Melphalan—ovarian cancer	8.85e-05	0.000896	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—ovarian cancer	8.83e-05	0.000894	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—ovarian cancer	8.8e-05	0.000892	CcSEcCtD
Vandetanib—Influenza—Epirubicin—ovarian cancer	8.8e-05	0.000892	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—ovarian cancer	8.77e-05	0.000888	CcSEcCtD
Vandetanib—Oedema—Paclitaxel—ovarian cancer	8.76e-05	0.000887	CcSEcCtD
Vandetanib—Muscle spasms—Docetaxel—ovarian cancer	8.74e-05	0.000886	CcSEcCtD
Vandetanib—Infection—Paclitaxel—ovarian cancer	8.7e-05	0.000881	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—ovarian cancer	8.64e-05	0.000875	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—ovarian cancer	8.63e-05	0.000874	CcSEcCtD
Vandetanib—Dizziness—Vinorelbine—ovarian cancer	8.61e-05	0.000872	CcSEcCtD
Vandetanib—Nervous system disorder—Paclitaxel—ovarian cancer	8.59e-05	0.00087	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—ovarian cancer	8.58e-05	0.000869	CcSEcCtD
Vandetanib—Thrombocytopenia—Paclitaxel—ovarian cancer	8.57e-05	0.000868	CcSEcCtD
Vandetanib—Skin disorder—Paclitaxel—ovarian cancer	8.51e-05	0.000861	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—ovarian cancer	8.47e-05	0.000857	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—ovarian cancer	8.43e-05	0.000854	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—ovarian cancer	8.34e-05	0.000845	CcSEcCtD
Vandetanib—Gefitinib—ABCB1—ovarian cancer	8.32e-05	0.016	CrCbGaD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	8.31e-05	0.000842	CcSEcCtD
Vandetanib—Vomiting—Vinorelbine—ovarian cancer	8.28e-05	0.000838	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—ovarian cancer	8.23e-05	0.000834	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—ovarian cancer	8.23e-05	0.000834	CcSEcCtD
Vandetanib—Rash—Vinorelbine—ovarian cancer	8.21e-05	0.000831	CcSEcCtD
Vandetanib—Dermatitis—Vinorelbine—ovarian cancer	8.2e-05	0.000831	CcSEcCtD
Vandetanib—Bosutinib—ABCB1—ovarian cancer	8.19e-05	0.0157	CrCbGaD
Vandetanib—Upper respiratory tract infection—Epirubicin—ovarian cancer	8.18e-05	0.000829	CcSEcCtD
Vandetanib—Headache—Vinorelbine—ovarian cancer	8.16e-05	0.000826	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—ovarian cancer	8.15e-05	0.000825	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—ovarian cancer	8.15e-05	0.000825	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—ovarian cancer	8.13e-05	0.000824	CcSEcCtD
Vandetanib—ABCC1—lymph node—ovarian cancer	8.08e-05	0.000789	CbGeAlD
Vandetanib—Photosensitivity reaction—Epirubicin—ovarian cancer	8.04e-05	0.000814	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—ovarian cancer	7.99e-05	0.00081	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—ovarian cancer	7.99e-05	0.000809	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	7.98e-05	0.000808	CcSEcCtD
Vandetanib—CYP3A4—female reproductive system—ovarian cancer	7.97e-05	0.000777	CbGeAlD
Vandetanib—Weight decreased—Epirubicin—ovarian cancer	7.97e-05	0.000807	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—ovarian cancer	7.94e-05	0.000804	CcSEcCtD
Vandetanib—Cough—Docetaxel—ovarian cancer	7.94e-05	0.000804	CcSEcCtD
Vandetanib—Insomnia—Paclitaxel—ovarian cancer	7.92e-05	0.000802	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—ovarian cancer	7.9e-05	0.0008	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—ovarian cancer	7.88e-05	0.000798	CcSEcCtD
Vandetanib—Paraesthesia—Paclitaxel—ovarian cancer	7.86e-05	0.000796	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—ovarian cancer	7.85e-05	0.000795	CcSEcCtD
Vandetanib—Infestation—Epirubicin—ovarian cancer	7.85e-05	0.000795	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—ovarian cancer	7.85e-05	0.000795	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—ovarian cancer	7.83e-05	0.000793	CcSEcCtD
Vandetanib—Dyspnoea—Paclitaxel—ovarian cancer	7.81e-05	0.000791	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	7.78e-05	0.000788	CcSEcCtD
Vandetanib—Arthralgia—Docetaxel—ovarian cancer	7.74e-05	0.000784	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—ovarian cancer	7.74e-05	0.000784	CcSEcCtD
Vandetanib—Nausea—Vinorelbine—ovarian cancer	7.73e-05	0.000783	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—ovarian cancer	7.72e-05	0.000781	CcSEcCtD
Vandetanib—Dyspepsia—Paclitaxel—ovarian cancer	7.71e-05	0.000781	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	7.69e-05	0.000779	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—ovarian cancer	7.65e-05	0.000775	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—ovarian cancer	7.63e-05	0.000773	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—ovarian cancer	7.63e-05	0.000773	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—ovarian cancer	7.62e-05	0.000771	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—ovarian cancer	7.62e-05	0.000771	CcSEcCtD
Vandetanib—Decreased appetite—Paclitaxel—ovarian cancer	7.61e-05	0.000771	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—ovarian cancer	7.57e-05	0.000767	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	7.57e-05	0.000767	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.56e-05	0.000766	CcSEcCtD
Vandetanib—Fatigue—Paclitaxel—ovarian cancer	7.55e-05	0.000765	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—ovarian cancer	7.53e-05	0.000762	CcSEcCtD
Vandetanib—Constipation—Paclitaxel—ovarian cancer	7.49e-05	0.000758	CcSEcCtD
Vandetanib—Pain—Paclitaxel—ovarian cancer	7.49e-05	0.000758	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—ovarian cancer	7.48e-05	0.000758	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.44e-05	0.000753	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—ovarian cancer	7.42e-05	0.000752	CcSEcCtD
Vandetanib—Oedema—Docetaxel—ovarian cancer	7.42e-05	0.000752	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—ovarian cancer	7.4e-05	0.00075	CcSEcCtD
Vandetanib—Infection—Docetaxel—ovarian cancer	7.37e-05	0.000747	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—ovarian cancer	7.37e-05	0.000746	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—ovarian cancer	7.36e-05	0.000746	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—ovarian cancer	7.35e-05	0.000744	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—ovarian cancer	7.31e-05	0.00074	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—ovarian cancer	7.28e-05	0.000737	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—ovarian cancer	7.27e-05	0.000736	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—ovarian cancer	7.26e-05	0.000736	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—ovarian cancer	7.26e-05	0.000736	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—ovarian cancer	7.21e-05	0.00073	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.2e-05	0.000729	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—ovarian cancer	7.17e-05	0.000727	CcSEcCtD
Vandetanib—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.16e-05	0.000725	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—ovarian cancer	7.14e-05	0.000723	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—ovarian cancer	7.08e-05	0.000717	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—ovarian cancer	7.08e-05	0.000717	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—ovarian cancer	7.06e-05	0.000715	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—ovarian cancer	7.06e-05	0.000715	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—ovarian cancer	7.05e-05	0.000714	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—ovarian cancer	6.96e-05	0.000705	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—ovarian cancer	6.93e-05	0.000701	CcSEcCtD
Vandetanib—Body temperature increased—Paclitaxel—ovarian cancer	6.92e-05	0.000701	CcSEcCtD
Vandetanib—Abdominal pain—Paclitaxel—ovarian cancer	6.92e-05	0.000701	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—ovarian cancer	6.91e-05	0.0007	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.87e-05	0.000696	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—ovarian cancer	6.85e-05	0.000694	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—ovarian cancer	6.81e-05	0.00069	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—ovarian cancer	6.79e-05	0.000688	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.76e-05	0.000685	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—ovarian cancer	6.71e-05	0.00068	CcSEcCtD
Vandetanib—ABCG2—lymph node—ovarian cancer	6.69e-05	0.000653	CbGeAlD
Vandetanib—Paraesthesia—Docetaxel—ovarian cancer	6.67e-05	0.000675	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—ovarian cancer	6.66e-05	0.000675	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—ovarian cancer	6.64e-05	0.000672	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—ovarian cancer	6.62e-05	0.00067	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—ovarian cancer	6.59e-05	0.000667	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—ovarian cancer	6.55e-05	0.000664	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—ovarian cancer	6.54e-05	0.000662	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—ovarian cancer	6.53e-05	0.000662	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—ovarian cancer	6.52e-05	0.00066	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—ovarian cancer	6.45e-05	0.000653	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—ovarian cancer	6.44e-05	0.000652	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.41e-05	0.000649	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—ovarian cancer	6.4e-05	0.000648	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—ovarian cancer	6.39e-05	0.000648	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—ovarian cancer	6.39e-05	0.000647	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—ovarian cancer	6.35e-05	0.000643	CcSEcCtD
Vandetanib—Pain—Docetaxel—ovarian cancer	6.35e-05	0.000643	CcSEcCtD
Vandetanib—Constipation—Docetaxel—ovarian cancer	6.35e-05	0.000643	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—ovarian cancer	6.3e-05	0.000638	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—ovarian cancer	6.28e-05	0.000636	CcSEcCtD
Vandetanib—Asthenia—Paclitaxel—ovarian cancer	6.28e-05	0.000636	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—ovarian cancer	6.23e-05	0.000631	CcSEcCtD
Vandetanib—Pruritus—Paclitaxel—ovarian cancer	6.2e-05	0.000627	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—ovarian cancer	6.17e-05	0.000625	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—ovarian cancer	6.17e-05	0.000624	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—ovarian cancer	6.13e-05	0.000621	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—ovarian cancer	6.09e-05	0.000617	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—ovarian cancer	6.07e-05	0.000615	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—ovarian cancer	6.05e-05	0.000613	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—ovarian cancer	6.01e-05	0.000608	CcSEcCtD
Vandetanib—Diarrhoea—Paclitaxel—ovarian cancer	5.99e-05	0.000607	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—ovarian cancer	5.92e-05	0.000599	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—ovarian cancer	5.9e-05	0.000597	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—ovarian cancer	5.88e-05	0.000595	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—ovarian cancer	5.87e-05	0.000594	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—ovarian cancer	5.87e-05	0.000594	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—ovarian cancer	5.82e-05	0.00059	CcSEcCtD
Vandetanib—Dizziness—Paclitaxel—ovarian cancer	5.79e-05	0.000586	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—ovarian cancer	5.78e-05	0.000586	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—ovarian cancer	5.76e-05	0.000584	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—ovarian cancer	5.71e-05	0.000579	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—ovarian cancer	5.68e-05	0.000575	CcSEcCtD
Vandetanib—Vomiting—Paclitaxel—ovarian cancer	5.57e-05	0.000564	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—ovarian cancer	5.56e-05	0.000563	CcSEcCtD
Vandetanib—Rash—Paclitaxel—ovarian cancer	5.52e-05	0.000559	CcSEcCtD
Vandetanib—Dermatitis—Paclitaxel—ovarian cancer	5.52e-05	0.000559	CcSEcCtD
Vandetanib—Headache—Paclitaxel—ovarian cancer	5.49e-05	0.000556	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—ovarian cancer	5.46e-05	0.000553	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—ovarian cancer	5.39e-05	0.000546	CcSEcCtD
Vandetanib—Cough—Epirubicin—ovarian cancer	5.35e-05	0.000542	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—ovarian cancer	5.35e-05	0.000542	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—ovarian cancer	5.33e-05	0.000539	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—ovarian cancer	5.32e-05	0.000538	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—ovarian cancer	5.3e-05	0.000536	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—ovarian cancer	5.25e-05	0.000532	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—ovarian cancer	5.22e-05	0.000529	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—ovarian cancer	5.22e-05	0.000529	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—ovarian cancer	5.2e-05	0.000527	CcSEcCtD
Vandetanib—Nausea—Paclitaxel—ovarian cancer	5.2e-05	0.000527	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.19e-05	0.000525	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—ovarian cancer	5.11e-05	0.000517	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—ovarian cancer	5.08e-05	0.000514	CcSEcCtD
Vandetanib—Oedema—Epirubicin—ovarian cancer	5.01e-05	0.000507	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—ovarian cancer	4.99e-05	0.000505	CcSEcCtD
Vandetanib—Infection—Epirubicin—ovarian cancer	4.97e-05	0.000504	CcSEcCtD
Vandetanib—Cough—Doxorubicin—ovarian cancer	4.95e-05	0.000502	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—ovarian cancer	4.92e-05	0.000498	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—ovarian cancer	4.91e-05	0.000497	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—ovarian cancer	4.91e-05	0.000497	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—ovarian cancer	4.9e-05	0.000496	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—ovarian cancer	4.9e-05	0.000496	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—ovarian cancer	4.86e-05	0.000492	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—ovarian cancer	4.83e-05	0.000489	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—ovarian cancer	4.83e-05	0.000489	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—ovarian cancer	4.82e-05	0.000488	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.8e-05	0.000486	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—ovarian cancer	4.73e-05	0.000479	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—ovarian cancer	4.72e-05	0.000478	CcSEcCtD
Vandetanib—Rash—Docetaxel—ovarian cancer	4.68e-05	0.000474	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—ovarian cancer	4.68e-05	0.000474	CcSEcCtD
Vandetanib—Headache—Docetaxel—ovarian cancer	4.65e-05	0.000471	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—ovarian cancer	4.63e-05	0.000469	CcSEcCtD
Vandetanib—Infection—Doxorubicin—ovarian cancer	4.6e-05	0.000466	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.56e-05	0.000462	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—ovarian cancer	4.54e-05	0.00046	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—ovarian cancer	4.54e-05	0.000459	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—ovarian cancer	4.53e-05	0.000459	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—ovarian cancer	4.5e-05	0.000456	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—ovarian cancer	4.5e-05	0.000455	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—ovarian cancer	4.46e-05	0.000452	CcSEcCtD
Vandetanib—Nausea—Docetaxel—ovarian cancer	4.41e-05	0.000447	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—ovarian cancer	4.41e-05	0.000446	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—ovarian cancer	4.35e-05	0.000441	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.32e-05	0.000438	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—ovarian cancer	4.32e-05	0.000437	CcSEcCtD
Vandetanib—Pain—Epirubicin—ovarian cancer	4.28e-05	0.000434	CcSEcCtD
Vandetanib—Constipation—Epirubicin—ovarian cancer	4.28e-05	0.000434	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.22e-05	0.000427	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—ovarian cancer	4.19e-05	0.000424	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—ovarian cancer	4.16e-05	0.000421	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—ovarian cancer	4.13e-05	0.000418	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.09e-05	0.000415	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—ovarian cancer	4.08e-05	0.000413	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—ovarian cancer	4.03e-05	0.000408	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4e-05	0.000405	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—ovarian cancer	3.99e-05	0.000404	CcSEcCtD
Vandetanib—Pain—Doxorubicin—ovarian cancer	3.96e-05	0.000401	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—ovarian cancer	3.96e-05	0.000401	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—ovarian cancer	3.96e-05	0.000401	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—ovarian cancer	3.96e-05	0.000401	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.79e-05	0.000384	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—ovarian cancer	3.66e-05	0.000371	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—ovarian cancer	3.66e-05	0.000371	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—ovarian cancer	3.59e-05	0.000364	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—ovarian cancer	3.54e-05	0.000359	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—ovarian cancer	3.43e-05	0.000347	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—ovarian cancer	3.32e-05	0.000337	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—ovarian cancer	3.31e-05	0.000335	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—ovarian cancer	3.28e-05	0.000332	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—ovarian cancer	3.18e-05	0.000322	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—ovarian cancer	3.17e-05	0.000321	CcSEcCtD
Vandetanib—Rash—Epirubicin—ovarian cancer	3.16e-05	0.00032	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—ovarian cancer	3.15e-05	0.000319	CcSEcCtD
Vandetanib—Headache—Epirubicin—ovarian cancer	3.14e-05	0.000318	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—ovarian cancer	3.06e-05	0.00031	CcSEcCtD
Vandetanib—Nausea—Epirubicin—ovarian cancer	2.97e-05	0.000301	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—ovarian cancer	2.95e-05	0.000298	CcSEcCtD
Vandetanib—Rash—Doxorubicin—ovarian cancer	2.92e-05	0.000296	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—ovarian cancer	2.92e-05	0.000296	CcSEcCtD
Vandetanib—Headache—Doxorubicin—ovarian cancer	2.9e-05	0.000294	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—ovarian cancer	2.75e-05	0.000279	CcSEcCtD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—ovarian cancer	1.31e-06	8.35e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—ovarian cancer	1.3e-06	8.33e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK1—ovarian cancer	1.3e-06	8.32e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—ovarian cancer	1.3e-06	8.32e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—ovarian cancer	1.3e-06	8.31e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—ovarian cancer	1.3e-06	8.31e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	1.3e-06	8.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—ovarian cancer	1.29e-06	8.28e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	1.29e-06	8.25e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—ovarian cancer	1.29e-06	8.24e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—ovarian cancer	1.29e-06	8.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	1.28e-06	8.2e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—ovarian cancer	1.27e-06	8.16e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—ovarian cancer	1.27e-06	8.16e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—ovarian cancer	1.27e-06	8.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—ovarian cancer	1.27e-06	8.15e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—ovarian cancer	1.27e-06	8.14e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—ovarian cancer	1.27e-06	8.12e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—ovarian cancer	1.27e-06	8.11e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—ovarian cancer	1.27e-06	8.1e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—ovarian cancer	1.26e-06	8.08e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—ovarian cancer	1.26e-06	8.08e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—ovarian cancer	1.26e-06	8.07e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—ovarian cancer	1.26e-06	8.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—ovarian cancer	1.26e-06	8.05e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—ovarian cancer	1.26e-06	8.05e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—ovarian cancer	1.25e-06	8.02e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—ovarian cancer	1.25e-06	8.01e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—ovarian cancer	1.25e-06	8e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	1.25e-06	7.99e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—ovarian cancer	1.25e-06	7.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—ovarian cancer	1.25e-06	7.97e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—ovarian cancer	1.25e-06	7.97e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—ovarian cancer	1.24e-06	7.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—ovarian cancer	1.24e-06	7.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—ovarian cancer	1.24e-06	7.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	1.24e-06	7.95e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—ovarian cancer	1.24e-06	7.91e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—ovarian cancer	1.23e-06	7.86e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—ovarian cancer	1.23e-06	7.85e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—ovarian cancer	1.23e-06	7.84e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—ovarian cancer	1.22e-06	7.8e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—ovarian cancer	1.22e-06	7.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—ovarian cancer	1.22e-06	7.78e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—ovarian cancer	1.21e-06	7.77e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—ovarian cancer	1.21e-06	7.76e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—ovarian cancer	1.21e-06	7.74e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—ovarian cancer	1.2e-06	7.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—ovarian cancer	1.2e-06	7.69e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—ovarian cancer	1.2e-06	7.68e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—ovarian cancer	1.2e-06	7.68e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—ovarian cancer	1.2e-06	7.68e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—ovarian cancer	1.2e-06	7.67e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	1.2e-06	7.66e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—ovarian cancer	1.2e-06	7.66e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—ovarian cancer	1.2e-06	7.65e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—ovarian cancer	1.19e-06	7.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	1.19e-06	7.64e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—ovarian cancer	1.19e-06	7.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	1.19e-06	7.59e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—ovarian cancer	1.18e-06	7.53e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.17e-06	7.49e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—ovarian cancer	1.17e-06	7.49e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—ovarian cancer	1.17e-06	7.48e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—ovarian cancer	1.17e-06	7.46e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.17e-06	7.46e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	1.16e-06	7.45e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—ovarian cancer	1.16e-06	7.41e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—ovarian cancer	1.15e-06	7.39e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	1.15e-06	7.38e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	1.15e-06	7.38e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—ovarian cancer	1.15e-06	7.37e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—ovarian cancer	1.15e-06	7.37e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—ovarian cancer	1.15e-06	7.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	1.15e-06	7.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—ovarian cancer	1.15e-06	7.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—ovarian cancer	1.15e-06	7.35e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—ovarian cancer	1.15e-06	7.34e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—ovarian cancer	1.14e-06	7.32e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—ovarian cancer	1.14e-06	7.31e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—ovarian cancer	1.14e-06	7.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—ovarian cancer	1.14e-06	7.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—ovarian cancer	1.13e-06	7.26e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—ovarian cancer	1.13e-06	7.26e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—ovarian cancer	1.13e-06	7.22e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—ovarian cancer	1.13e-06	7.22e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—ovarian cancer	1.13e-06	7.2e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—ovarian cancer	1.12e-06	7.2e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—ovarian cancer	1.12e-06	7.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	1.12e-06	7.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—ovarian cancer	1.12e-06	7.18e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—ovarian cancer	1.12e-06	7.16e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—ovarian cancer	1.12e-06	7.15e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—ovarian cancer	1.12e-06	7.15e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FASN—ovarian cancer	1.11e-06	7.13e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—ovarian cancer	1.11e-06	7.12e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—ovarian cancer	1.11e-06	7.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—ovarian cancer	1.11e-06	7.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—ovarian cancer	1.11e-06	7.09e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—ovarian cancer	1.11e-06	7.09e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—ovarian cancer	1.11e-06	7.09e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—ovarian cancer	1.1e-06	7.07e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	1.1e-06	7.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.1e-06	7.05e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—ovarian cancer	1.1e-06	7.04e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—ovarian cancer	1.1e-06	7.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.1e-06	7.02e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—ovarian cancer	1.09e-06	7e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—ovarian cancer	1.09e-06	6.96e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—ovarian cancer	1.09e-06	6.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—ovarian cancer	1.08e-06	6.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—ovarian cancer	1.08e-06	6.92e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—ovarian cancer	1.08e-06	6.91e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—ovarian cancer	1.08e-06	6.9e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—ovarian cancer	1.07e-06	6.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—ovarian cancer	1.07e-06	6.87e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—ovarian cancer	1.07e-06	6.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	1.07e-06	6.85e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—ovarian cancer	1.06e-06	6.8e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—ovarian cancer	1.06e-06	6.8e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—ovarian cancer	1.06e-06	6.79e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—ovarian cancer	1.06e-06	6.79e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	1.06e-06	6.79e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—ovarian cancer	1.06e-06	6.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—ovarian cancer	1.06e-06	6.78e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—ovarian cancer	1.06e-06	6.78e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.06e-06	6.78e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—ovarian cancer	1.06e-06	6.76e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—ovarian cancer	1.05e-06	6.73e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—ovarian cancer	1.05e-06	6.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	1.05e-06	6.7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	1.05e-06	6.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	1.05e-06	6.7e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—ovarian cancer	1.04e-06	6.68e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—ovarian cancer	1.04e-06	6.67e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—ovarian cancer	1.04e-06	6.66e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—ovarian cancer	1.04e-06	6.64e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—ovarian cancer	1.03e-06	6.62e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—ovarian cancer	1.03e-06	6.61e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—ovarian cancer	1.03e-06	6.56e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—ovarian cancer	1.03e-06	6.56e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—ovarian cancer	1.02e-06	6.54e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—ovarian cancer	1.02e-06	6.52e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—ovarian cancer	1.02e-06	6.5e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.02e-06	6.5e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—ovarian cancer	1.01e-06	6.46e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—ovarian cancer	1.01e-06	6.46e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—ovarian cancer	1.01e-06	6.46e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—ovarian cancer	1e-06	6.42e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—ovarian cancer	1e-06	6.4e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—ovarian cancer	9.99e-07	6.39e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—ovarian cancer	9.99e-07	6.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—ovarian cancer	9.94e-07	6.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	9.9e-07	6.33e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—ovarian cancer	9.82e-07	6.28e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—ovarian cancer	9.75e-07	6.24e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—ovarian cancer	9.74e-07	6.24e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—ovarian cancer	9.73e-07	6.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	9.69e-07	6.2e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—ovarian cancer	9.69e-07	6.2e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—ovarian cancer	9.64e-07	6.17e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—ovarian cancer	9.61e-07	6.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—ovarian cancer	9.6e-07	6.14e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—ovarian cancer	9.57e-07	6.13e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—ovarian cancer	9.57e-07	6.13e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—ovarian cancer	9.57e-07	6.12e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—ovarian cancer	9.54e-07	6.1e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—ovarian cancer	9.49e-07	6.07e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—ovarian cancer	9.39e-07	6.01e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—ovarian cancer	9.37e-07	6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—ovarian cancer	9.34e-07	5.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—ovarian cancer	9.25e-07	5.92e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—ovarian cancer	9.24e-07	5.91e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—ovarian cancer	9.23e-07	5.9e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—ovarian cancer	9.23e-07	5.9e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—ovarian cancer	9.22e-07	5.9e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—ovarian cancer	9.22e-07	5.9e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—ovarian cancer	9.21e-07	5.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	9.17e-07	5.87e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—ovarian cancer	9.16e-07	5.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	9.09e-07	5.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	9.01e-07	5.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—ovarian cancer	8.92e-07	5.71e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	8.9e-07	5.7e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—ovarian cancer	8.85e-07	5.66e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—ovarian cancer	8.84e-07	5.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—ovarian cancer	8.83e-07	5.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	8.79e-07	5.63e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—ovarian cancer	8.76e-07	5.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	8.72e-07	5.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—ovarian cancer	8.61e-07	5.51e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—ovarian cancer	8.59e-07	5.5e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—ovarian cancer	8.56e-07	5.48e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—ovarian cancer	8.53e-07	5.46e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—ovarian cancer	8.51e-07	5.45e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—ovarian cancer	8.48e-07	5.43e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—ovarian cancer	8.45e-07	5.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	8.41e-07	5.38e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—ovarian cancer	8.41e-07	5.38e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—ovarian cancer	8.41e-07	5.38e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—ovarian cancer	8.36e-07	5.35e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—ovarian cancer	8.27e-07	5.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—ovarian cancer	8.24e-07	5.27e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—ovarian cancer	8.23e-07	5.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—ovarian cancer	8.21e-07	5.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—ovarian cancer	8.19e-07	5.24e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—ovarian cancer	8.17e-07	5.23e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—ovarian cancer	8.17e-07	5.23e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—ovarian cancer	8.16e-07	5.22e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—ovarian cancer	8.11e-07	5.19e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	8.05e-07	5.15e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—ovarian cancer	7.94e-07	5.08e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—ovarian cancer	7.88e-07	5.04e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—ovarian cancer	7.85e-07	5.02e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—ovarian cancer	7.82e-07	5.01e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—ovarian cancer	7.76e-07	4.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—ovarian cancer	7.61e-07	4.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	7.57e-07	4.84e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—ovarian cancer	7.53e-07	4.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—ovarian cancer	7.44e-07	4.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—ovarian cancer	7.44e-07	4.76e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	7.43e-07	4.75e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—ovarian cancer	7.39e-07	4.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—ovarian cancer	7.32e-07	4.69e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	7.3e-07	4.67e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—ovarian cancer	7.27e-07	4.65e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—ovarian cancer	7.16e-07	4.58e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—ovarian cancer	7.06e-07	4.52e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—ovarian cancer	7.03e-07	4.5e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—ovarian cancer	7e-07	4.48e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—ovarian cancer	6.9e-07	4.42e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—ovarian cancer	6.75e-07	4.32e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—ovarian cancer	6.7e-07	4.29e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—ovarian cancer	6.62e-07	4.23e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—ovarian cancer	6.46e-07	4.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—ovarian cancer	6.46e-07	4.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—ovarian cancer	6.25e-07	4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—ovarian cancer	6.18e-07	3.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	6.03e-07	3.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—ovarian cancer	5.98e-07	3.82e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—ovarian cancer	5.96e-07	3.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—ovarian cancer	5.72e-07	3.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	5.3e-07	3.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—ovarian cancer	5.28e-07	3.38e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—ovarian cancer	5.22e-07	3.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	4.62e-07	2.96e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—ovarian cancer	4.26e-07	2.73e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—ovarian cancer	3.99e-07	2.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.82e-07	1.8e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—ovarian cancer	2.3e-07	1.47e-06	CbGpPWpGaD
